Navigation Links
JCI table of contents: Aug. 9, 2007
Date:8/13/2007

org">jeff.molkentin@cchmc.org.

Steven R. Houser
Temple University School of Medicine, Philadelphia, Pennsylvania, USA.
Phone: (215) 707-3278; Fax: (215) 707-0170; E-mail: srhouser@temple.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=31060


CARDIOLOGY: Extent of apoptotic cell death affects risk factor for heart failure

Changes in the size, shape, and function of the heart (cardiac remodeling) contribute to the onset and progression of heart failure. Adverse cardiac remodeling occurs in mice engineered to have sustained inflammation in the heart (MHCsTNF mice) and is accompanied by increased death of the muscle cells of the heart (cardiomyocytes) by a process known as apoptosis and decreased cardiomyocyte expression of the anti-apoptotic protein Bcl-2.

In a study that appears online on August 9 in advance of publication in the September print issue of the Journal of Clinical Investigation, Douglas Mann and colleagues from Baylor College of Medicine, Houston, do not observe adverse cardiac remodeling in MHCsTNF mice engineered to constitutively express Bcl-2 in their cardiomyocytes. However, although cardiomyocyte apoptosis was decreased, it was not completely eliminated. Further analysis revealed that Bcl-2 inhibited only one pathway of apoptosis activated by the sustained inflammatory response the intrinsic apoptotic pathway of cell death. The extrinsic apoptotic pathway of cell death proceeded unchecked. These data led the authors to suggest that the extent of cardiomyocyte apoptosis is a critical factor in determining whether or not adverse cardiac remodeling occurs.

TITLE: TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways

AUTHOR CONTACT:
Douglas L. Mann
Baylor College of Medicine,
'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Highly adaptable genome in gut bacterium key to intestinal health
2. Development of portable infectious disease detector
3. Scientists identify genes responsible for black rot disease in vegetables
4. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
5. Aloe vera coating may prolong freshness, safety of fruits and vegetables
6. Nanotechnology to provide portable genetic risk detection
7. New study shows patients more willing to consider self-injectable HIV therapy than many physicians anticipate
8. Implantable pumps extend lives of patients too sick for transplant
9. Bioengineers create stable networks of blood vessels
10. Portable cocaine sensor developed at UC Santa Barbara
11. Researchers develop portable vein finder for faster, more accurate injections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/3/2014)... Research and Markets has announced the ... Markets and Companies" to their offering. ... which have already started to play an important role in ... the old fashioned bone marrow transplants. Role of cells in ... become a part of medical practice. Stem cells ...
(Date:11/3/2014)...  NeuroSigma ® , Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ... neurological and neuropsychiatric disorders, announced today that the ... Notice of Allowance for Mexican Patent Application No. ... and the Regents of the University of California ...
(Date:11/2/2014)... of Physics World , James Dacey explores the ... death" to take their innovations from the lab into ... challenge facing all start-up companies as they move from ... of two main factors: physics-based inventions are usually far ... out to be a lot more complicated than had ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2
... Ariz. (Sept. 13, 2012) -- Shane Snyder, who earlier ... Water Works Association (AWWA), has been invited to present ... 3,500 at the 2012 International Water Association,s (IWA) World ... professor,s presentation will focus not only on his research ...
... Scientists have found the answer to why female killer whales have ... their adult sons. Led by the Universities of Exeter and York ... the research shows that, for a male over 30, the death ... his death within the following year. The reason for the ...
... of bioengineering at Stanford University, has won a Director,s ... award includes a five-year, $2.5 million grant to be ... to affect a broad area of biomedical or behavioral ... to explore the use of synthetic biology platforms and ...
Cached Biology News:UA engineering professor Shane Snyder to speak in Korea on international water quality 2Long menopause allows killer whales to care for adult sons 2Long menopause allows killer whales to care for adult sons 3
(Date:11/23/2014)... WI (PRWEB) November 23, 2014 ... and supplier of fine chemical ingredients to the ... the launch of its new website, Apiscent.com. , ... of Apiscent Labs, clean design, easy navigation, rotating ... make Apiscent Labs stand out. , ...
(Date:11/22/2014)... During his lifetime Richard L. Sharp was a ... with great people and take risks to achieve success. ... at his extraordinarily courageous attitude when taking on challenges. ... with his death impending—that’s how he continued looking for ... take his life. , Carrying on Sharp’s relentless dream ...
(Date:11/22/2014)... 21, 2014 CannLabs, Inc. ... analytics and scientific testing methodologies relating to cannabis, today ... $750,000 line of credit from an existing stockholder of ... have secured this commitment from one of our existing ... CannLabs. “This capital will help accelerate our planned expansions ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed outperformed 137 ... Summit in San Francisco to take first place in ... Valley investors and technology elites as the premier showcase ... Briteseed to move on to the final phase ... with other elite innovation finalists for a $125,000 cash ...
Breaking Biology Technology:Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3CannLabs Secures $750,000 Line Of Credit 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3
... proxy, FOR the Election of, Two ... May 15 /PRNewswire/ - The Concerned Shareholders of Biovail ... (TSX:BVF) continues to mislead its shareholders by making the ... requisition was simply about governance reform and has already ...
... Nile Therapeutics, Inc. (Nasdaq: NLTX ... therapeutics for heart failure patients, received notification from the ... has released the Company,s CD-NP development program from clinical ... the FDA the finalized protocol for the Company,s planned ...
... Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced ... 15 Proteolix, Inc. today announced that data from ... solid tumors will be presented at the 2009 Annual ... being held May 29 - June 2, 2009 in ...
Cached Biology Technology:The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 2The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 3The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 4The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 5The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 6The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 7Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 2Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 3Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 2Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 3
... Thermal Cycler (MBS) is a ... medium to high throughput PCR. ... latest in satellite block technology, ... control, resulting in a system ...
...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
CQCS kit for etra KR 4i , (other units)....
Biology Products: